Standard BioTools Inc. (NASDAQ: LAB) is a Healthcare company (Medical - Specialties) with a market capitalization of $213M. The Maz Rating grades it against the other companies in its sector.
Standard BioTools Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.54, Standard BioTools Inc. trades at 2.4x sales and 0.4x book value, with an EV/EBITDA of 0.3. Over the last twelve months it generated about $87M of revenue and a net loss of $45M. It runs a gross margin of 50.8%, an operating margin of -90.6% and a net margin of -46.4%. It shows return on equity of -7.5%, return on invested capital of -6.6% and a free cash flow yield of -30.2%. On the balance sheet: a debt-to-equity ratio of 0.05 and a current ratio of 9.75. Over the past 52 weeks the share price ranged from $0.39 to $1.72, with a beta of 1.35.
Standard BioTools Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 6 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Standard BioTools Inc. (LAB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.28% / 30% · (Cash+Inv) / Mkt Cap (36m) 213.0% / 30% · Interest income / Revenue 25.2% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 2.28% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 175.5% / 33% · Receivables / Mkt Cap (36m) 4.94% / 49% · Interest income / Revenue 25.2% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 2.28% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 175.5% / 33.33% · Receivables / Mkt Cap (24m) 4.94% / 33.33% · Interest income / Revenue 25.2% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.50% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 64.0% / 33.33% · Receivables / Avg Assets (4Q) 2.38% / 33.33% · Interest income / Revenue 25.2% / 5% | Fail |
| FTSE | Debt / Total Assets 0.94% / 33.33% · (Cash+ST Inv) / Total Assets 72.6% / 33.33% · (Cash+Recv) / Total Assets 74.6% / 33.33% · Interest income / Revenue 25.2% / 5% | Fail |
No. As of September 2026, Standard BioTools Inc. (LAB) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Standard BioTools Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 25.2% of each dividend: Standard BioTools Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.